Genelux Corporation (NasdaqCM: GNLX)
Health Care · Biotechnology · US
$2.73
+0.37% today · -27.3% 1Y
Genelux Corporation (NasdaqCM: GNLX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $121.89M and employs 26 people.
Over the last twelve months the share price has lost 27.3%, trading between 2.29 and 8.54.
Tweenvest scores Genelux Corporation across four factors: quality 28/100. Its strongest factor is quality.
GNLX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $121.89M
- Revenue (TTM)
- $8.00K
- P/E
- —
- EPS
- -0.86
- Dividend yield
- —
- Beta (5Y)
- 0.59
- 52-week high
- $8.54
- 52-week low
- $2.29
- Avg volume (3M)
- —
- Shares outstanding
- 44.81M
- Employees
- 26
- Next earnings
- —
About Genelux Corporation
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
- ISIN
- US36870H1032
- Founded
- 2001
- Listed since
- Jan 26, 2023
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.